Zainab Mbbs Nazir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zainab Mbbs Nazir has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Ariful Haque
Department of Orthopedic Surgery, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan, China
11 shared publications - Ashna Habib
Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan
11 shared publications - Tooba Ali
Dow University Of Health Sciences Karachi Pakistan
10 shared publications - Ajeet Singh
Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan
3 shared publications - Hafsa Mbbs Ghouri
Dow University of Health Sciences, Karachi, Pakistan
2 shared publications - Hamza Irfan
Department of Medicine Shaikh Khalifa Bin Zayed Al Nahyan Medical and Dental College Lahore Pakistan
2 shared publications
Latest Publications
- Open Access
- 6 February 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (5) , 2524-2525
Zelsuvmi: a novel approach to treating molluscum contagiosum
An abstract is unavailable. This article is available as a PDF only.
- 6 February 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (5) , 2524-2525
Open AccessZelsuvmi: a novel approach to treating molluscum contagiosum
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 23 August 2024
- Published by Wolters Kluwer Health in International Journal of Surgery: Global Health
- Vol. 7 (5)
The unseen burden: the tangled web of paternal postpartum depression and childhood resilience
Postpartum depression (PPD) is a significant mental health disorder that has received little attention (both clinically and experimentally) and is underdiagnosed. PPD is most associated with mothers after giving birth. However, it may also affect fathers for unknown reasons. Poverty, a family history of depression, and hormonal changes are all risk factors for PPD in fathers. Although not much is known about paternal PPD, research indicates that it is often 8.7% prevalent in the first year, peaking between 3 and 6 months after childbirth (9.2%).
- 23 August 2024
- Published by Wolters Kluwer Health in International Journal of Surgery: Global Health
- Vol. 7 (5)
Open AccessThe unseen burden: the tangled web of paternal postpartum depression and childhood resilience
Postpartum depression (PPD) is a significant mental health disorder that has received little attention (both clinically and experimentally) and is underdiagnosed. PPD is most associated with mothers after giving birth. However, it may also affect fathers for unknown reasons. Poverty, a family history of depression, and hormonal changes are all risk factors for PPD in fathers. Although not much is known about paternal PPD, research indicates that it is often 8.7% prevalent in the first year, peaking between 3 and 6 months after childbirth (9.2%).
- Open Access
- 20 May 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (7) , 3816-3819
Xylazine in illicit drug mixtures: a growing threat and overlooked danger
An abstract is unavailable. This article is available as a PDF only.
- 20 May 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (7) , 3816-3819
Open AccessXylazine in illicit drug mixtures: a growing threat and overlooked danger
An abstract is unavailable. This article is available as a PDF only.
- Top Cited PapersOpen Access
- 15 May 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (8) , 4555-4559
Revolutionary breakthrough: FDA approves CASGEVY, the first CRISPR/Cas9 gene therapy for sickle cell disease
Sickle cell disease (SCD) is a hereditary hemoglobinopathy resulting from a β-globin chain mutation that causes abnormal hemoglobin (HbS) polymerization and leads to severe complications. Current treatment options primarily focus on symptom management, with limited curative potential. Recently, Casgevy, the first CRISPR/Cas9-based gene therapy for SCD, has received breakthrough FDA approval. Clinical trials have shown that Casgevy administered to patients aged older than or equal to 12 years enables precise modifications in hematopoietic stem cells, resulting in elevated fetal hemoglobin (HbF) levels and a significant reduction in vaso-occlusive events. Unlike conventional treatments, this therapy offers a curative approach and eliminates the need for recurrent transfusions and transplants, thereby improving the quality of life of patients with SCD. Casgevy has emerged as a beacon of hope for SCD patients and signifies a potential paradigm shift in SCD management due to its safety, curative potential, and transformative impact, positioning it as a groundbreaking intervention. Nevertheless, ethical considerations surrounding CRISPR technology and regulatory frameworks must be addressed to ensure responsible application and equitable access to this one-time gene editing therapy. As the authors celebrate this scientific advancement, sustained interdisciplinary collaboration and ethical scrutiny are essential to navigating the evolving landscape of CRISPR technology in medicine. This review aims to provide a detailed insight into the application of Casgevy, challenges associated with its application, future prospects of this therapy, and its comparison with existing treatment options for SCD.
- 15 May 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (8) , 4555-4559
Top Cited PapersOpen AccessRevolutionary breakthrough: FDA approves CASGEVY, the first CRISPR/Cas9 gene therapy for sickle cell disease
Sickle cell disease (SCD) is a hereditary hemoglobinopathy resulting from a β-globin chain mutation that causes abnormal hemoglobin (HbS) polymerization and leads to severe complications. Current treatment options primarily focus on symptom management, with limited curative potential. Recently, Casgevy, the first CRISPR/Cas9-based gene therapy for SCD, has received breakthrough FDA approval. Clinical trials have shown that Casgevy administered to patients aged older than or equal to 12 years enables precise modifications in hematopoietic stem cells, resulting in elevated fetal hemoglobin (HbF) levels and a significant reduction in vaso-occlusive events. Unlike conventional treatments, this therapy offers a curative approach and eliminates the need for recurrent transfusions and transplants, thereby improving the quality of life of patients with SCD. Casgevy has emerged as a beacon of hope for SCD patients and signifies a potential paradigm shift in SCD management due to its safety, curative potential, and transformative impact, positioning it as a groundbreaking intervention. Nevertheless, ethical considerations surrounding CRISPR technology and regulatory frameworks must be addressed to ensure responsible application and equitable access to this one-time gene editing therapy. As the authors celebrate this scientific advancement, sustained interdisciplinary collaboration and ethical scrutiny are essential to navigating the evolving landscape of CRISPR technology in medicine. This review aims to provide a detailed insight into the application of Casgevy, challenges associated with its application, future prospects of this therapy, and its comparison with existing treatment options for SCD.
- Open Access
- 22 February 2024
- Published by Wolters Kluwer Health in International Journal of Surgery Open
- Vol. 62 (2) , 176-177
A call to action: gastric cancer in low- and middle-income nations and the value of screening
- 22 February 2024
- Published by Wolters Kluwer Health in International Journal of Surgery Open
- Vol. 62 (2) , 176-177
Open AccessA call to action: gastric cancer in low- and middle-income nations and the value of screening
- Open Access
- 16 February 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (5) , 2529-2531
Revolutionizing gastric linitis plastica diagnosis: the crucial role of EUS-FNA in a sequential diagnostic approach
An abstract is unavailable. This article is available as a PDF only.
- 16 February 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (5) , 2529-2531
Open AccessRevolutionizing gastric linitis plastica diagnosis: the crucial role of EUS-FNA in a sequential diagnostic approach
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 14 February 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (5) , 2520-2522
Addressing the urgency: advocating for the inclusion of meningococcal vaccine in Pakistan’s immunization program
An abstract is unavailable. This article is available as a PDF only.
- 14 February 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (5) , 2520-2522
Open AccessAddressing the urgency: advocating for the inclusion of meningococcal vaccine in Pakistan’s immunization program
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 7 February 2024
- Published by Wiley in Clinical Case Reports
- Vol. 12 (2) , e8481
Co‐occurrence of Guillain–Barre syndrome and rheumatoid arthritis in a young female: A case report from a low middle‐income country
Key Clinical Message: We present the case of an adult female who had rheumatoid arthritis at first but later tested positive for Guillain–Barré syndrome (GBS). In symptomatic GBS patients (related to large joints), physicians (and therapists) should consider rheumatoid arthritis when risk factors are present. The co‐existence of GBS and other autoimmune disorders is uncommon. We present the case of an adult female who had rheumatoid arthritis at first but later tested positive for GBS. Further details are provided regarding the interdisciplinary diagnostic and therapy strategy that led to the patient's complete recovery. An adult female patient with rheumatoid arthritis presented with progressive weakness in her lower limbs, affecting her arm and causing numbness in her left hand and bilateral lower limbs. She has not passed stool for the last 2 days and has experienced gastroenteritis with watery, profuse diarrhea. On admission, the patient was awake, alert, and able to communicate. She had a thorough history of vital signs, with no signs of dehydration, jaundice, pallor, or edema. The patient's lower limbs were hypotonic and her upper limbs were normal. She experienced loss of sensation in her lower limbs, vibration, and proprioception. The patient's EMG‐NCS report indicated sensory and motor axonal neuropathy (AMSAN variant). Plasmapheresis sessions were finished in our patient, and a very good result was achieved. In symptomatic GBS patients (related to large joints), physicians (and therapists) should consider rheumatoid arthritis when risk factors are present. Appropriate clinical treatment, which includes prompt evaluation of alternate diagnoses in the case of therapeutic failure, can improve patient outcomes.
- 7 February 2024
- Published by Wiley in Clinical Case Reports
- Vol. 12 (2) , e8481
Open AccessCo‐occurrence of Guillain–Barre syndrome and rheumatoid arthritis in a young female: A case report from a low middle‐income country
Key Clinical Message: We present the case of an adult female who had rheumatoid arthritis at first but later tested positive for Guillain–Barré syndrome (GBS). In symptomatic GBS patients (related to large joints), physicians (and therapists) should consider rheumatoid arthritis when risk factors are present. The co‐existence of GBS and other autoimmune disorders is uncommon. We present the case of an adult female who had rheumatoid arthritis at first but later tested positive for GBS. Further details are provided regarding the interdisciplinary diagnostic and therapy strategy that led to the patient's complete recovery. An adult female patient with rheumatoid arthritis presented with progressive weakness in her lower limbs, affecting her arm and causing numbness in her left hand and bilateral lower limbs. She has not passed stool for the last 2 days and has experienced gastroenteritis with watery, profuse diarrhea. On admission, the patient was awake, alert, and able to communicate. She had a thorough history of vital signs, with no signs of dehydration, jaundice, pallor, or edema. The patient's lower limbs were hypotonic and her upper limbs were normal. She experienced loss of sensation in her lower limbs, vibration, and proprioception. The patient's EMG‐NCS report indicated sensory and motor axonal neuropathy (AMSAN variant). Plasmapheresis sessions were finished in our patient, and a very good result was achieved. In symptomatic GBS patients (related to large joints), physicians (and therapists) should consider rheumatoid arthritis when risk factors are present. Appropriate clinical treatment, which includes prompt evaluation of alternate diagnoses in the case of therapeutic failure, can improve patient outcomes.
- Open Access
- 6 February 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (5) , 3085-3087
Healthcare challenges in LMICs: addressing antibiotic resistance threats, a call for comprehensive global solutions: an editorial
- 6 February 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (5) , 3085-3087
Open AccessHealthcare challenges in LMICs: addressing antibiotic resistance threats, a call for comprehensive global solutions: an editorial
- Open Access
- 14 December 2023
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (3) , 1836-1838
Milestone in infant health: unveiling the RSV vaccine’s shielding effect for newborns
An abstract is unavailable. This article is available as a PDF only.
- 14 December 2023
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (3) , 1836-1838
Open AccessMilestone in infant health: unveiling the RSV vaccine’s shielding effect for newborns
An abstract is unavailable. This article is available as a PDF only.